(Q36284232)

13 August 2017

Decitabine: a historical review of the development of an epigenetic drug (English)

1 reference

13 August 2017

Dick de Vos

1

1 reference

PubMed ID

16220311

13 August 2017

Wendy van Overveld

series ordinal

2

1 reference

13 August 2017

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

84 Suppl 1

1 reference

13 August 2017

3-8

1 reference

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

13 August 2017

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00277-005-0008-X

The differentiation of myeloid leukaemia cells: new possibilities for therapy

21 January 2018

1 reference

12 December 2020

Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer

1 reference

12 December 2020

Epigenetics in human disease and prospects for epigenetic therapy

1 reference

12 December 2020

Phase I trial of continuous infusion 5-aza-2'-deoxycytidine

1 reference

12 December 2020

Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia

1 reference

12 December 2020

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

12 December 2020

Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside

1 reference

12 December 2020

Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group

1 reference

12 December 2020

5-AZA-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation

1 reference

12 December 2020

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

1 reference

12 December 2020

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

1 reference

12 December 2020

Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).

1 reference

12 December 2020

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias

1 reference

12 December 2020

5-Aza-2'-Deoxycytidine and DNA Methyltransferase Inhibitors in the Treatment of Myeloid Leukemias and Myelodysplastic Syndromes: Biological Aspects and Clinical Results. Proceedings of a workshop. Rome, Italy, November 3, 1991

1 reference

12 December 2020

Evaluation of an inhibitor of DNA methylation, 5-aza-2'-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy

1 reference

12 December 2020

Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine

1 reference

12 December 2020

Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients

1 reference

12 December 2020

Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia

1 reference

12 December 2020

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

1 reference

12 December 2020

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

12 December 2020

Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase.

1 reference

12 December 2020

DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia

1 reference

12 December 2020

The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

1 reference

12 December 2020

Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides

1 reference

12 December 2020

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

12 December 2020

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

12 December 2020

MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE

1 reference

12 December 2020

Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice

1 reference

12 December 2020

Cellular differentiation, cytidine analogs and DNA methylation

1 reference

12 December 2020

Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer

1 reference

12 December 2020

Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix

1 reference

12 December 2020

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

12 December 2020

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

1 reference

12 December 2020

Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase

1 reference

12 December 2020

2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia

1 reference

12 December 2020

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

1 reference

12 December 2020

5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix

1 reference

12 December 2020

10.1007/S00277-005-0008-X

Identifiers

DOI

1 reference

13 August 2017

0 references

1 reference

PubMed ID

16220311